Search results
Results from the WOW.Com Content Network
Below are the 5-year relative survival rates for the two most common types of NHL in the United States – diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) – based on people diagnosed between 2012 and 2018.
What are survival rates for diffuse large B-cell lymphoma? According to the National Cancer Institute, 64.6% of people with DLBCL are alive five years after diagnosis. (Relative survival rates are estimates based on large groups of people.)
Using statistical models for analysis, age-adjusted rates for new diffuse large B-cell lymphoma cases have been falling on average 0.8% each year over 2012–2021. Age-adjusted death rates have been stable over 2012–2021. 5-year relative survival trends are shown below.
Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 25 percent of NHL cases [1,2]. (See "Classification of hematopoietic neoplasms".) The diagnostic category of DLBCL is morphologically, genetically, and biologically heterogeneous.
The American Cancer Society reports that the overall five-year survival rate for DLBCL is 65 percent. This overall survival rate is calculated based on information from people across the United States who were diagnosed with this blood cancer between 2012 and 2018.
Many individuals with diffuse large B-cell lymphoma are cured within four to five months of combined chemotherapy and rituximab. However, patients receiving therapy for diffuse large B-cell lymphoma can experience serious complications, including infections and organ dysfunction.
The updated World Health Organization (WHO) classification has refined the categorization of large B-cell lymphomas, which are a heterogeneous collection of clinicopathological entities (Table 1),...